Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery

Oct 01, 2008

Sirtris, a GSK company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it published a new review article on the growing body of sirtuin research and its potential to treat diseases of aging such as Type 2 Diabetes, mitochondrial disorders, inflammation, cancer, and heart disease. Entitled "SIRTUINS – Novel Therapeutic Targets to Treat Age-Associated Diseases," the review appears in today's issue of the journal Nature Reviews Drug Discovery.

Sirtuins are a family of enzymes which target genes that control aging. There are a total of seven sirtuin enzymes that exist in mammals. SIRT1 is the founding member of this class of enzymes and is currently the most studied of the group. When activated, SIRT1 appears to mimic some of the positive health effects seen in calorie-restricted animals.

"We are excited to be at the forefront of this research, which continues to intensify as we see positive results from early human clinical studies," said Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, a GSK company. "The body of clinical data supporting the role of SIRT1 activation as a viable mechanism for treating a broad range of diseases of metabolism and aging is growing."

Peter Elliott, Ph.D., Senior Vice President of Development, said, "At Sirtris, we are targeting the genes which control the aging process with the potential to treat diseases of aging such as diabetes, neurodegeneration, cancer, and inflammation."

This review highlights the molecular mechanism of action of sirtuins with a view towards diseases where SIRT1 activation shows therapeutic promise. Such diseases of aging include Type 2 Diabetes and mitochondrial disorders, cardiovascular disease, cancer, neurodegeneration and inflammatory diseases. One of the first small molecules discovered to exhibit the positive effects of calorie restriction is resveratrol, a natural ingredient found in red wine. Since then, Sirtris has developed its own proprietary formulation of resveratrol, SRT501. Early clinical studies in patients with Type 2 Diabetes indicate that SRT501 may lower glucose and improve insulin sensitivity. Sirtris also has new chemical entities (NCEs) which are structurally unrelated to and one-thousand times more potent than resveratrol. Sirtris' first new chemical entity is currently being evaluated for safety and tolerability in a Phase 1a study in humans.

"We are beginning to understand more about activation of other enzymes in the sirtuin family, SIRT2-7, and we're encouraged by early data that indicates a role for other sirtuins in multiple therapeutic areas," continued Dr. Westphal.

Source: Pure Communications Inc.

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Health checks will be seated by Sharp

Dec 08, 2014

(Phys.org) —Sharp unveiled a news-making prototype of a sensor earlier this month at Semicon Japan 2014, which took place from Dec 3 to 5. As its title suggests, Sharp's "Blood Vessel Aging Degree Sensor" ...

Early stress in starlings found to lead to faster aging

Dec 03, 2014

(Phys.org) —A combined team of researchers from Newcastle University and the University of Glasgow, both in the U.K. has found that stress in young starlings can lead to shortened telomeres—which prior ...

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

dirk_bruere
not rated yet Oct 02, 2008
No new info, just PR blurb. A waste of space

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.